Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT.
[en] The role of umbilical cord blood transplantation (CBT) in acute myeloid leukemia (AML) patients with active disease at allogeneic hematopoietic cell transplantation (allo-HCT) remains poorly investigated. In this study, we compared transplantation outcomes of 2963 patients with primary refractory or relapsed AML given CBT, 10/10 HLA-matched UD, or 9/10 HLA-matched UD allo-HCT from 2004 to 2015 at EBMT-affiliated centers. Neutrophil engraftment and complete remission rates in CBT, UD 10/10, and UD 9/10 recipients were 75 and 48%, 93 and 69%, and 93 and 70%, respectively. In multivariate Cox analyses, in comparison with CBT (n = 285), UD 10/10 recipients (n = 2001) had a lower incidence of relapse (HR = 0.7, P = 0.001), a lower incidence of non relapse mortality (HR = 0.6, P < 0.001), better GVHD-free and leukemia-free survival (GRFS, HR = 0.8, P < 0.001) and better survival (HR = 0.6, P < 0.001). Further, in comparison with CBT, 9/10 UD recipients (n = 677) also had a lower incidence of relapse (HR = 0.8, P = 0.02), a lower incidence of nonrelapse mortality (HR = 0.7, P = 0.008), better GRFS (HR = 0.8, P = 0.01) and better survival (HR = 0.7, P < 0.001). In summary, these data suggest that in AML patients with active disease at transplantation, allo-HCT with UD results in better transplantation outcomes than CBT.
Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT.
Brissot, E. et al. Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. J. Hematol. Oncol. 10(1), 130 (2017).
Gyurkocza, B., Lazarus, H. M. & Giralt, S. Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy. Bone Marrow Transplant. 52(8), 1083–1090 (2017).
Baron, F. et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia 26(12), 2462–2468 (2012).
Baron, F. et al. Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukemia: a report from Eurocord and the ALWP of the EBMT. J. Intern. Med. 283(2), 178–189 (2018).
Dickinson, A. M. et al. Graft-versus-leukemia effect following hematopoietic stem cell transplantation for leukemia. Front. Immunol. 8, 496 (2017).
Weisdorf, D. et al. Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis. Biol. Blood Marrow Transplant. 20(6), 816–822 (2014).
Ruggeri, A. et al. Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. Leukemia 28(4), 779–786 (2014).
Eapen, M. et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 11(7), 653–660 (2010).
Baron, F. et al. Impact of donor type in patients with AML given allogeneic hematopoietic cell transplantation after low-dose TBI-based regimen. Clin. Cancer Res. 24(12), 2794–2803. 10.1158/1078-0432.CCR-17-3622 (2018).
Milano, F. et al. Cord-blood transplantation in patients with minimal residual disease. N. Engl. J. Med. 375(10), 944–953 (2016).
Baron, F. et al. Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT. J. Hematol. Oncol. 10(1), 128 (2017).
Baron, F. et al. RIC versus MAC UCBT in adults with AML: a report from Eurocord, the ALWP and the CTIWP of the EBMT. Oncotarget 7(28), 43027–43038 (2016).
Glucksberg, H. et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18, 295–304 (1974).
Ruggeri, A., Labopin, M., Ciceri, F., Mohty, M. & Nagler, A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 51(4), 610–611 (2016).
McCaffrey, D. F. et al. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat. Med. 32(19), 3388–3414 (2013).
Hiwarkar, P. et al. Cord blood transplantation recapitulates fetal ontogeny with a distinct molecular signature that supports CD4(+) T-cell reconstitution. Blood Adv. 1(24), 2206–2216 (2017).
Admiraal, R. et al. Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation. Blood 128(23), 2734–2741 (2016).
Delaney, C., Bollard, C. M. & Shpall, E. J. Cord blood graft engineering. Biol. Blood Marrow Transplant. 19(1 Suppl), S74–78 (2013).
Baron, F., Ruggeri, A. & Nagler, A. Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications. Exp. Rev. Hematol 9(3), 297–314. 10.1586/17474086.2016.1128321 (2016).
Wagner, J. E. Jr. et al. Phase I/II trial of stem Regenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft. Cell Stem Cell 18(1), 144–155 (2016).
